Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma.
about
Radioiodine Treatment and Thyroid Hormone Suppression Therapy for Differentiated Thyroid Carcinoma: Adverse Effects Support the Trend toward Less Aggressive Treatment for Low-Risk PatientsLow BMI and low TSH value as risk factors related to lower bone mineral density in postmenospausal women under levothyroxine therapy for differentiated thyroid carcinoma.The Presence of Thyroid-Stimulation Blocking Antibody Prevents High Bone Turnover in Untreated Premenopausal Patients with Graves' Disease.A 2016 Italian Survey about Guidelines and Clinical Management of Thyroid Nodules.Update on the treatment of hypothyroidismEffect of Thyrotropin Suppression Therapy on Bone in Thyroid Cancer PatientsRole of Thyroid Hormones in Skeletal Development and Bone Maintenance.Therapeutic Strategies and Clinical Outcome in Papillary Thyroid Microcarcinoma: A Multicenter Observational Study.Thyrotropin Stimulates Differentiation Not Proliferation of Normal Human Thyrocytes in Culture.Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.Thyroid nodules and cancer management guidelines: comparisons and controversies.Clinical features of recently diagnosed papillary thyroid carcinoma in elderly patients aged 65 and older based on 10 years of sonographic experience at a single institution in KoreaLong-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer.Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study.Actions of pituitary hormones beyond traditional targets.
P2860
Q26797677-96447A36-818D-41AF-8FF6-FEED22AC9552Q35760578-7020CCA0-DC23-4520-A154-E5274B4DF058Q36358885-3C3FDAEC-5214-41A2-B3D1-5687DE0895C5Q36394563-92BE01EE-93EA-4AC4-8783-25726874C5A3Q36425038-90393BFC-518A-4650-B74F-7EE9AD477DC3Q36558392-A4E1268B-313D-4540-81C0-832FAEADF145Q36773018-62A2EDB5-595C-4A19-9392-ADF9EE46050DQ37387862-21FF17C5-F94D-4C05-9EFC-AEE950E007A6Q37531700-3EFF1758-5081-417F-A75A-BD8EE58B984DQ38716870-A32BA78D-5CB9-4736-92AD-C29FBAA6E411Q38783191-FEE23F33-32B0-4E5F-B243-797AF90E97DBQ41895964-096DCB28-72C8-47FD-87AA-83B0B3C6F432Q47212485-A87AB653-1C78-4AEA-9916-19CD84777675Q47700549-1116CF75-C453-4D44-B147-3D335915D080Q52647974-023DAA59-AF35-41C0-9560-7FA00774054F
P2860
Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Thyrotropin suppression increa ...... ferentiated thyroid carcinoma.
@en
Thyrotropin suppression increa ...... ferentiated thyroid carcinoma.
@nl
type
label
Thyrotropin suppression increa ...... ferentiated thyroid carcinoma.
@en
Thyrotropin suppression increa ...... ferentiated thyroid carcinoma.
@nl
prefLabel
Thyrotropin suppression increa ...... ferentiated thyroid carcinoma.
@en
Thyrotropin suppression increa ...... ferentiated thyroid carcinoma.
@nl
P2093
P356
P1433
P1476
Thyrotropin suppression increa ...... fferentiated thyroid carcinoma
@en
P2093
Andrew W Smith
Azhar Mahrous
Frank L Palmer
James A Fagin
Laura Boucai
Laura Y Wang
R Michael Tuttle
Snehal G Patel
P304
P356
10.1089/THY.2014.0287
P577
2014-12-16T00:00:00Z